FORECAST-II Feasibility of using Organoid Response to inform treatments for patients with Colorectal cancer staring first-line therapy

Walter and Eliza Hall Institute of Medical Research0 个研究点目标入组 140 人开始时间: 2024年5月29日最近更新: 2024年9月9日

适应症

试验速览

暂无简介。

•1 Be able to provide informed, voluntary, written consent.
•2 Have a diagnosis of CRC that is either locally advanced and unresectable, or metastatic.
•3 Have ECOG performance status of 0-2.
•4 Have adequate major organ function.
•5 Be fit to receive systemic treatment.
•6 Be planning to receive systemic treatment.
•7 Have chemotherapy-naïve disease in the advanced setting. Prior chemotherapy in the
•neo/adjuvant setting is permitted for those with relapsed disease.
•8 Have a life expectancy of > 3 months.
•9 Be accessible for follow up and data collection.
•10 Be willing and able to undergo initial tumour biopsy and provide serial blood samples.
•11 Be willing to provide archival tumour tissue or fresh tumour tissue for genetic testing

•1 Cannot undergo biopsy of tumour tissue either due to patient factors (such as being unable to withhold anticoagulation) or tumour factors (location, size inappropriate to biopsy).
•2 Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant’s participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
•3 Has a known psychiatric or substance abuse disorder that would interfere with the participant’s ability to cooperate with the requirements of the study.

发起方

Walter and Eliza Hall Institute of Medical Research